PharmaVentures announced today that it acted as advisor to the Dow Chemical Company (NYSE:DOW) for the sale of Dowpharma Small Molecules business to Dr. Reddy’s Laboratories (NYSE:RDY).
PharmaVentures announced today the appointment of Anne Vindenes Allen MSc as Chief Operating Officer of PharmaDeals, the new publishing division of PharmaVentures Ltd. Fintan Walton, PhD, PharmaVentures’ Chief Executive Officer says, “We have a large and loyal following for the PharmaDeals database within the pharmaceutical and biotechnology business sector, and have plans to roll out some truly exciting developments in the coming months. We are delighted Anne will join us to steer these developments. Her experience of managing complex web technology implementations combined with her publishing expertise will be invaluable in helping us position our products to better serve our discerning customers.”
With over 24,000 deals and alliances completed in the Life Science industry over the past 10 years, current and readily available statistics and insight is an essential part of business development. PharmaVentures, a leading provider of specialist consultancy and intelligence services, has launched a bespoke on-demand, 48 hour turn-around analysis service, PharmaDeals® Research.
The revolutionary global media channel for the pharmaceutical and biotech industry, PharmaTelevision, is celebrating its one year anniversary. Launched on May 18th 2006 and with viewing figures now averaging 8,000 per programme, the site is fast becoming one of the most popular channels for insight and intelligence across the industry.
Increasing demand for its services in the USA has led PharmaVentures, a leading provider of specialist consultancy and intelligence services, to appoint Jim McCarthy as its dedicated Vice President based in the United States.
Charles Macfarlane joins the Board of PharmaVentures as Non-Executive Director. PharmaVentures assists pharmaceutical and biotechnology companies worldwide in all aspects of deal making.
In response to growing industry demand, PharmaVentures, a leading provider of specialist consultancy and intelligence services, has launched a series of training programmes to provide business executives from across the world with the essential skills necessary to manage and negotiate multi-million dollar agreements.
If Pfizer and Wyeth merge to create a $60 billion company, will it be a good deal or a bad deal? Fintan Walton, PhD, CEO of PharmaVentures, says, ‘This is potentially a bad deal for both companies. By 2012, the merged company will have lost $25bn with products coming off-patent with the current pipeline only replenishing $2.5bn in that time’.
PharmaVentures, the transaction advisory and media company, announced today the launch of its new product, PharmaDeals v2, a database of deals and alliances for the pharmaceuticals sector.
PharmaVentures announced today an agreement with Growthink Research, the U.S.-based market research firm, to distribute its Venture Capital database to customers in industry and academic institutions worldwide.